NuvOx Therapeutics, Inc. S-1/Aamended IPO prospectus

Executive Summary

NuvOx develops intravenous oxygen therapeutics for hospital-treated patients; it has no approved products and earns almost entirely grant revenue. Its priority is advancing NanO₂ in glioblastoma, stroke and acute respiratory distress syndrome, with glioblastoma results the next major test. Revenue remains small, and 9M 2026 net loss was $(7.01)M despite reduced clinical spending. At the assumed midpoint, the all-primary IPO would raise $20.0M gross at an implied $93.5M market capitalization, giving buyers 21.4% of outstanding shares. Buyers are funding clinical proof rather than commercial growth, and further financing will be needed before a regulatory submission.

Business Model and Growth Drivers

NanO₂ is an intravenous emulsion intended to deliver oxygen to oxygen-starved tissue alongside standard treatment. In glioblastoma, the intended benefit is to strengthen radiation’s tumor-killing effect; stroke and respiratory-distress programs seek to protect tissue or improve oxygenation. An early glioblastoma study reported median survival of 591 days in 11 patients vs 444 days in historical controls, but that small, nonrandomized comparison cannot establish efficacy. NuvOx’s strategy is to validate this single therapeutic across several indications, not build a portfolio of independent clinical-stage drugs.

• Glioblastoma: The randomized Phase IIb RESTORE trial completed enrollment and treatment of 93 patients. Final results are anticipated in early 2027; positive results are a prerequisite for pivotal Phase III development.
• Stroke: The investigator-sponsored UK NOVEL trial had treated 27 of ≈150 planned patients by 10/22/2026. U.S. development has Food and Drug Administration Fast Track designation, which does not establish efficacy.
• Respiratory distress: The Canadian Phase Ib trial has reported preliminary oxygenation signals. Health Canada authorized a planned 56-patient Phase II trial.
• Revenue model: Grants reimburse qualifying costs or milestones, rather than demonstrate customer demand. Future sales would depend on approval, hospital adoption and reimbursement against existing treatments, devices and competing experimental therapies.

The Offering

• Size and implied valuation: The unpriced offering comprises 2,860,000 primary shares at $6.00–$8.00: $17.2M–$22.9M gross, $80.1M–$107M market capitalization and a 21.4% buyer stake, using 13,350,208 post-offering shares. That equals 81.7–109 times FY2025 revenue, although revenue is almost entirely grants.
• Additional dilution: Including outstanding options and warrants, representative warrants and anticipated executive options gives 15,556,709 fully diluted shares, implying $93.3M–$124M capitalization and an 18.4% IPO-buyer stake before exercise proceeds. This excludes 68,750 unallocated plan shares; anticipated executive grants require approval.
• Execution: ThinkEquity leads the offering, contingent on NYSE American approval under “NUOX.” Its 45-day option covers 429,000 additional shares. Estimated net proceeds at $7.00 are ≈$17.4M, or ≈$20.2M with full exercise.
• Proceeds: The company receives the money: $5.0M for current glioblastoma completion, $1.0M for Phase III preparation, $6.0M for Phase II respiratory distress, $0.5M each for stroke supply and Phase Ib respiratory completion, and ≈$4.4M for development and working capital.
• Asset backing: Each $7.00 share would have $1.00 of net tangible assets behind it after the IPO—a $6.00 gap. Existing holders’ average stated purchase price is $2.11.
• Capital reset and resale: Preferred stock converts into 3.19M common shares; notes with $12.9M principal and accrued interest convert into 3.83M shares; a grant liability adds 45,620 shares. Existing securityholders generally face six-month lockups, and directors and executives twelve months, delaying substantial resale supply.

Key Financial Highlights

Amounts in $M. FY2024 is restated; interim results are unaudited. “After IPO” assumes conversions and the base offering at $7.00, including financing-cost and warrant-liability reclassifications.

• Accounting vs cash: 9M 2026 included $7.20M of convertible-instrument valuation losses, partly offset by a $4.22M amendment gain. Estimated contractual obligations changed value; neither movement represents operating cash earned or spent.
• Equity bridge: Accumulated losses of $43.3M drive negative equity. Conversions reduce fair-value liabilities by $25.9M, leaving equity at $(4.01)M before offering proceeds and adjustments make it positive.
• Funding need: Management estimated $10.0M of additional financing for the next twelve months. Expected proceeds cover at least twelve months, but not the later studies needed for approval.

Governance and Control

• Voting: Common shares carry one vote each after preferred conversion. Officers and directors hold 36.8% beneficial ownership; Executive Chairman Evan Unger holds 25.0%, including the family trust. A staggered board limits rapid shareholder-led change.
• Equity incentives: Outstanding and anticipated executive options total 1.82M shares, or 11.7% of the fully diluted count above. Existing options have $5.62M implied intrinsic value at $7.00 vs 9M 2026 stock-based compensation of $1.38M.
• Conflicts: Unger-related interests own the leased operating facility, while insiders hold convertible notes. Unger also leads Microvascular Therapeutics, creating competing commitments and related-party oversight needs.

Risk Assessment

• Reporting and continuity: The auditor flags going-concern doubt; FY2024 was restated, and clinical-accrual and financing-valuation control weaknesses remain unremediated.
• Financing dependence: Cash is insufficient without financing, some notes are past maturity, and IPO funding does not finance pivotal development through approval.
• Single-drug exposure: All clinical programs depend on NanO₂; efficacy remains unconfirmed, and potentially related serious adverse events could constrain development.
• Manufacturing bottleneck: FluoroMed is the sole active-ingredient supplier, Tucson has no backup facility, and manufacturing is not commercially validated.
• Rights uncertainty: Commercial use of UK stroke results requires funder consent without agreed terms; highlighted patents expire from 2031–2035.
• Key personnel: Nine employees depend heavily on Wang, Unger and Johnson; losing their expertise could disrupt trials, financing and execution.
• Valuation: An 81.7–109-times grant-revenue valuation requires clinical success and additional capital, not merely continued grant receipts.

What to Watch

• Glioblastoma readout: Early-2027 results must turn the 93-patient randomized trial into evidence supporting Phase III; weak efficacy or safety findings would undermine the lead program.
• Broader validation: UK stroke enrollment and Canadian respiratory trials must substantiate early signals; delays, adverse events or failure to secure commercial data rights would weaken expansion.
• Runway: Later filings should show proceeds funding the specified trials; faster depletion or another raise before completion would expose a funding shortfall.